From April 16 to April 19, the fifth International specialized exhibition-forum Healthcare of the Urals – 2024 was held at the Ekaterinburg-Expo IEC, where the Medsintez Plant, one of the key participants of this project, traditionally presented its products at the booth. This year, the focus was on equipping the medical system in the regions of Russia. The focus on import independence in the current conditions also remains one of the key ones. 160 manufacturers and suppliers of medical products from 34 cities of Russia, which presented over a thousand pieces of various equipment, took part in the event.

 

The opening ceremony of the event was attended by Deputy Governor of the Sverdlovsk Region Pavel Krekov, Minister of Health of the Sverdlovsk Region Andrey Karlov, Minister of Industry and Science of the Sverdlovsk Region Sergey Perestoronin, Chairman of the Committee of the Legislative Assembly of the Sverdlovsk Region for Social Policy Vyacheslav Pogudin, as well as President of the Ural Chamber of Commerce and Industry Andrey Besedin.

 

Pavel Krekov greeted the participants of the exhibition-forum and noted the importance of holding the event regularly. "The exhibition has become a landmark. This year, more than 30 regions of the Russian Federation are taking part in it. Here, industry experts can discuss the localization of production, import substitution, issues of healthcare development in both technical and organizational aspects, as well as conclude new contracts and sign agreements," the Deputy Governor of the Sverdlovsk Region noted.

 

Minister of Health of the Sverdlovsk Region Andrei Karlov read out a welcoming address from the Minister of Health of the Russian Federation Mikhail Murashko, noting that the exhibition-forum Healthcare of the Urals makes a tangible contribution to the development of domestic medicine, uniting the efforts of the best experts in the industry to find effective solutions to pressing problems in the field of healthcare.

 

The booth of the Medsintez Plant attracted wide attention of participants and visitors of the exhibition. The top officials of the region invited to the opening ceremony also appreciated the high production capabilities and prospects of the Plant. The booth of the Plant presented their own biotechnological drugs of world-class quality – genetically engineered and analog human insulins Rosinsulin, the first Russian preparation of human follicle-stimulating hormone (FSH) for treatment of human infertility Primapur, as well as the latest developments – hypoglycemic drugs for treatment type 2 diabetes mellitus Liraglutide and Semaglutide, preparation of human chorionic gonadotropin (HCG) and the first Russian preparations of veterinary insulin Vinsuvet. Also, a wide range of infusion solutions and the original domestic antiviral drug Triazavirin, effective against influenza, ARVI and COVID-19, were presented at the booth. Alexander Petrov, the Chairman of the Board of Directors of the Medsintez Plant, told the distinguished guests of the exhibition about own developments and future projects of the enterprise.

 

The modern full-cycle biotechnological enterprise Medsintez Plant has been presented on the Russian market for more than 20 years and it is an active participant in the implementation of drug import substitution programs in the Russian Federation.

 

Since 2009, the Medsintez Plant has been providing sustainable medicine supply for Russian patients with diabetes. Today, the Plant has launched the full-cycle production of the entire line of products of genetically engineered human insulin Rosinsulin and analogue insulins – Rosinsulin Aspart R and Rosinsulin Glargine from its own substances. The insulin preparations are produced in the most convenient and familiar dosage forms for consumers – in vials, cartridges and injection pens. The Medsintez Plant has developed and patented the design of disposable and reusable injection pens that ensure high precision dosing of the preparation. The production capacity of the site allows covering up to 100% of the Russian market's demand for insulin preparations.

 

More than 20 thousand children have already been born in Russia thanks to the treatment of patients using Primapur – the first Russian FSH drug for treatment of human infertility. The preparation is used in the IVF procedure and is included in the List of Vital and Essential Drugs. The Medsintez Plant is ready to meet the annual demand for FSH preparations in Russia by 200%. Today, the Plant is developing other hormonal preparations used in the complex of assisted reproductive technologies, such as human chorionic gonadotropin (HCG), Cetrorelix and Ganirelix, which will allow creating a full range of these drugs and ensure drug safety in this area in Russia.

 

The Plant can provide substantial support to the country during epidemics or pandemics of diseases caused by viruses. Since 2014, the Medsintez Plant produces the substance and the finished dosage form of Triazavirin, an original Russian preparation with proven direct antiviral activity against a wide range of RNA viruses. Triazavirin is included in the federal clinical recommendations of the Ministry of Health of Russia for treatment of influenza and ARVI in adults and this is the only direct-acting antiviral drug approved for the prevention of COVID-19.

 

During the coronavirus pandemic, Triazavirin saved dozens of lives – more than 2.5 million patients with COVID-19, influenza and ARVI received therapy using the drug. In 2020, many studies were carried out, thanks to which the drug was included in a number of guidelines, protocols for treatment and prevention of COVID-19, influenza and ARVI, including the standard for the diagnosis and treatment of the novel coronavirus infection in military personnel of the Armed Forces of the Russian Federation.

 

In 2022, clinical studies of the efficacy and safety of the drug at 100 mg dosage in children aged 12–17 years with a diagnosis of acute respiratory viral infections were successfully completed. Today, the drug is undergoing clinical trials in children aged 6 to 11 years.

 

In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs for treating type 2 diabetes mellitus: Liraglutide and Semaglutide. Domestic production of glucagon-like peptide-1 receptor agonists (GLP-1) will make it possible to bridge the shortage of similar drugs that arose in the country back in 2022, associated with the cessation of supplies from foreign manufacturers The production capacity of the Plant can meet 100% of Russia’s demand for these drugs.

 

In 2023, the company launched the production of the first Russian species-specific insulins for veterinary use, Vinsuvet (separately for cats and dogs). In the absence of the foreign drug on the Russian market, our own production of veterinary insulin will become a reliable support for pet owners in caring for their pets’ health.

 

Medsintez Plant LLC is one of the key enterprises of the Sverdlovsk Region in the field of healthcare. The enterprise is the basic organization of regional associations, such as the Ural Biomedical Cluster and the Association of Medical and Pharmaceutical Manufacturers of the Sverdlovsk Region. To a great extent, the Plant contributed to uniting regional scientific, innovative, production, commercial and personnel potential within these organizations. The priority for the Medsintez Plant throughout its 20-year history has been national drug safety.